FIA
MDGL icon

FNY Investment Advisers’s Madrigal Pharmaceuticals MDGL Stock Holding History

FNY Investment Advisers’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11
Closed -$2 – 639
2024
Q1 		$2 Buy
+11
New +$2.59K ﹤0.01% 587

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FNY Investment Advisers's MDGL Position: Q4 2025 in Review

FNY Investment Advisers sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 7 shares — an estimated $3K sold.

FNY Investment Advisers first reported a position in MDGL in Q2 2018 and held it in 4 quarters. The position peaked at $121K in Q1 2023. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • FNY Investment Advisers reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 7 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $3K.
  • FNY Investment Advisers first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • FNY Investment Advisers's Madrigal Pharmaceuticals position peaked at $121K in Q1 2023.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.